GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » EV-to-EBIT

Tourmaline Bio (Tourmaline Bio) EV-to-EBIT : -10.79 (As of May. 12, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Tourmaline Bio's Enterprise Value is $169.34 Mil. Tourmaline Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-15.70 Mil. Therefore, Tourmaline Bio's EV-to-EBIT for today is -10.79.

The historical rank and industry rank for Tourmaline Bio's EV-to-EBIT or its related term are showing as below:

TRML' s EV-to-EBIT Range Over the Past 10 Years
Min: -163.53   Med: 0   Max: 39.83
Current: -10.79

During the past 3 years, the highest EV-to-EBIT of Tourmaline Bio was 39.83. The lowest was -163.53. And the median was 0.00.

TRML's EV-to-EBIT is ranked worse than
100% of 433 companies
in the Biotechnology industry
Industry Median: 9.43 vs TRML: -10.79

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Tourmaline Bio's Enterprise Value for the quarter that ended in Dec. 2023 was $329.90 Mil. Tourmaline Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-15.70 Mil. Tourmaline Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -4.76%.

Tourmaline Bio EV-to-EBIT Historical Data

The historical data trend for Tourmaline Bio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio EV-to-EBIT Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBIT
- - -7.27

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial - - - - -7.27

Competitive Comparison of Tourmaline Bio's EV-to-EBIT

For the Biotechnology subindustry, Tourmaline Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tourmaline Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's EV-to-EBIT falls into.


Tourmaline Bio EV-to-EBIT Calculation

Tourmaline Bio's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=169.338/-15.698
=-10.79

Tourmaline Bio's current Enterprise Value is $169.34 Mil.
Tourmaline Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tourmaline Bio  (NAS:TRML) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Tourmaline Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-15.698/329.902368
=-4.76 %

Tourmaline Bio's Enterprise Value for the quarter that ended in Dec. 2023 was $329.90 Mil.
Tourmaline Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tourmaline Bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio (Tourmaline Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » EV-to-EBIT
Comparable Companies
CYTK NUVL KRYS CRSP INSM FOLD BPMC IMGN AXSM ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Website
https://www.tourmalinebio.com
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.